Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials
Meshkat S, Kwan A, Le G, Wong S, Teopiz K, Wang L, Rosenblat J, Rhee T, Cao B, McIntyre R. Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials. Journal Of Affective Disorders 2024 PMID: 39638064, DOI: 10.1016/j.jad.2024.12.008.Peer-Reviewed Original ResearchOrexin receptor antagonistsHamilton Depression Rating ScaleDepression Rating ScaleDepressive disorderQuick Inventory of Depressive Symptomatology Self-ReportReceptor antagonistInventory of Depressive Symptomatology Self-ReportDepressive symptoms compared to placeboMontgomery-Asberg Depression Rating ScaleRating ScaleDepressive Symptomatology Self-ReportMADRS total scoreSymptoms compared to placeboTreatment of depressionDecreased depression scoresQIDS-SRMDD patientsMontgomery-AsbergManaging depressive symptomsRandomized clinical trialsOrexin antagonistsDepression treatmentDepressive symptomsTreating insomniaCompared to placeboA systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
Menon T, Lee S, Gong X, Wong S, Le G, Kwan A, Teopiz K, Ho R, Cao B, Rhee T, Jing Zheng Y, Valentino K, Lin K, Vinberg M, Lo H, McIntyre R. A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain. CNS Spectrums 2024, 1-7. PMID: 39582175, DOI: 10.1017/s1092852924000531.Peer-Reviewed Original ResearchPsychiatric medicationsEffects of GLP-1RAsReceptor agonistsEfficacy of GLP-1 receptor agonistsRandomized controlled trialsGLP-1RAsModerate weight changeMitigate weight gainPsychiatric populationsPsychotropic drugsCognitive processesWeight gainClinically meaningful effectGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsSystematic reviewPreliminary evidenceGlucose-lowering agentsLong-term safetyWeight changeMeaningful effectEfficacy profilePersonsAbnormal weightClinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale.
Kaster T, Babujee A, Sharpe I, Rhee T, Gomes T, Kurdyak P, Foussias G, Wijeysundera D, Blumberger D, Vigod S. Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale. The Canadian Journal Of Psychiatry 2024, 7067437241290181. PMID: 39529283, PMCID: PMC11562932, DOI: 10.1177/07067437241290181.Peer-Reviewed Original ResearchSchizophrenia spectrum disordersInpatient electroconvulsive therapySeverity of psychotic symptomsAdministration of electroconvulsive therapyElectroconvulsive therapyPsychotic symptomsPatient-level characteristicsDiagnosis of schizophrenia spectrum disorderRates of substance use disordersObsessive-compulsive disorderSymptoms of psychosisAnti-psychotic medicationPopulation-level cross-sectional studySubstance use disordersOutpatient mental health service useEvidence-based treatmentsMental health service usePresence of catatoniaHealth service useClinical characteristicsPsychiatric inpatientsCharacteristics of inpatientsClinical characteristics of inpatientsComorbid depressionMulti-variable logistic regressionA systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders
Au H, Zheng Y, Le G, Wong S, Phan L, Teopiz K, Kwan A, Rhee T, Rosenblat J, Ho R, McIntyre R. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders. Journal Of Affective Disorders 2024, 370: 321-327. PMID: 39515485, DOI: 10.1016/j.jad.2024.11.019.Peer-Reviewed Original ResearchDorsal default mode networkFunctional connectivityMental disordersAssociated with decreased functional connectivityAssociated with increased functional connectivityRight frontal-parietal networkLateral orbitofrontal cortexFrontal-parietal networkDefault mode networkIncreased functional connectivityBrain functional connectivityBrain functional activityGlucagon-like peptide-1Orbitofrontal cortexPsychopathological domainsSalience networkVisuospatial networkMode networkParietal networkPsychiatric disordersBrain circuitsNeural circuitsGLP-1RAsGlucagon-like peptide-1 receptor activationReceptor agonistsEfficacy of esketamine for perinatal depression: a systematic review and meta-analysis.
Wong S, Le G, Kwan A, Teopiz K, Rhee T, Ho R, Rosenblat J, Mansur R, McIntyre R. Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis. CNS Spectrums 2024, 1-9. PMID: 39479775, DOI: 10.1017/s1092852924000452.Peer-Reviewed Original ResearchPostpartum depressionPerinatal depressionPrevention of postpartum depressionIncidence of postpartum depressionReduced health-related quality of lifeHealth-related quality of lifeSystematic reviewTreatment of postpartum depressionWeeks of childbirthMeta-analysisWeeks post-deliveryClinically meaningful implicationsQuality of lifeRandomized controlled trialsRandom-effects modelDecreased incidencePain managementPostpartum periodChildbirth laborIncidence ratePost-deliveryPsychosocial functioningEligibility criteriaControlled trialsPrimary outcomeNational Trends in and Concentration of Industry Payments to U.S. Psychiatrists, 2015-2021.
Havlik J, Ososanya L, Tang D, Wahid S, Ross J, Rhee T. National Trends in and Concentration of Industry Payments to U.S. Psychiatrists, 2015-2021. Psychiatric Services 2024, appips20240218. PMID: 39439279, DOI: 10.1176/appi.ps.20240218.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)
McIntyre R, Mansur R, Rosenblat J, Rhee T, Cao B, Teopiz K, Wong S, Le G, Ho R, Kwan A. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®). Journal Of Affective Disorders 2024, 369: 922-927. PMID: 39433133, DOI: 10.1016/j.jad.2024.10.062.Peer-Reviewed Original ResearchGLP-1 RAsReporting Odds RatioFood and Drug AdministrationFDA Adverse Event Reporting SystemGLP-1European Medicines AgencyMeasures of suicidalityWorld Health OrganizationGlucagon-like peptide-1 receptor agonistsGlucagon-like peptide 1 receptor agonistsWorld Health Organization pharmacovigilance databasePeptide-1 receptor agonistsPeptide 1 receptor agonistsUnited States Food and Drug AdministrationRA exposureStates Food and Drug AdministrationSuicidal behaviorSuicidal ideationAdverse Event Reporting SystemSuicideReceptor agonistsEvent Reporting SystemSemaglutideOdds ratioPharmacovigilance databaseEfficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchConceptsBipolar depressionAcute seriesRisk of affective switchDiagnosis of bipolar depressionRefractory bipolar depressionAcute phaseMADRS scoreAffective switchIntranasal esketamineManic episodesBipolar disorderCohort of patientsAttending psychiatristsSource of morbidityEsketamineSample of patientsIV ketamineMaintenance treatmentDepressionClinical responseHeightened riskClinical outcomesMania/hypomaniaKetamineKetamine/esketamineCorrection: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial
Kwan A, Lakhani M, Le G, Singh G, Teopiz K, Ceban F, Nijjar C, Meshkat S, Badulescu S, Ho R, Rhee T, Di Vincenzo J, Gill H, McIntyre R. Correction: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial. European Archives Of Psychiatry And Clinical Neuroscience 2024, 274: 1967-1968. PMID: 39307886, DOI: 10.1007/s00406-024-01910-z.Peer-Reviewed Original ResearchElectroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
Le G, Wong S, Lu A, Vasudeva S, Gill H, Badulescu S, Portelles D, Zheng Y, Teopiz K, Meshkat S, Kwan A, Ho R, Rhee T, Rosenblat J, Mansur R, McIntyre R. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review. Journal Of Affective Disorders 2024, 368: 798-819. PMID: 39299586, DOI: 10.1016/j.jad.2024.09.081.Peer-Reviewed Original ResearchReuptake inhibitorsDepressive disorderPathophysiology of depressive disordersSystematic reviewAssociated with SSRIsClass of SSRIsNorepinephrine reuptake inhibitorsDoses of antidepressantsSerotonin reuptake inhibitorsFDA-approved agentsVortioxetine treatmentBlock reuptakeAntidepressant exposureSerotonin transporterSNRISSRIsVortioxetineDatabase inceptionConverging evidenceFunctional connectivitySerotoninNeural activityElectroencephalography signaturesStudy investigated changesInhibitorsAssociation between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis
Le G, Wong S, Au H, Badulescu S, Gill H, Vasudeva S, Teopiz K, Rhee T, Ho R, Kwan A, Mansur R, Rosenblat J, McIntyre R. Association between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 368: 513-527. PMID: 39303880, DOI: 10.1016/j.jad.2024.09.118.Peer-Reviewed Original ResearchSuicidal ideationMood disordersPsychiatric disordersLifetime history of suicide attemptsHealthy controlsHistory of suicide attemptsMeasures of ruminationSuicide attempt historyDiagnosed mood disorderTransdiagnostic associationsAttempt historyDepressive disorderNeurobiological substratesSuicide completersLifetime historyGeneral cognitionSuicide attemptsMeta-analysisIdeationSystematic reviewMoodClinically meaningful associationsSuicideResearch vistasFunctional impairmentSubjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial
Kwan A, Lakhani M, Le G, Singh G, Teopiz K, Ceban F, Nijjar C, Meshkat S, Badulescu S, Ho R, Rhee T, Di Vincenzo J, Gill H, McIntyre R. Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled Trial. European Archives Of Psychiatry And Clinical Neuroscience 2024, 274: 1959-1966. PMID: 39190040, DOI: 10.1007/s00406-024-01877-x.Peer-Reviewed Original ResearchDigit Symbol Substitution TestMeasures of cognitive functionPDQ-20Cognitive functionPerceived Deficits QuestionnairePost-COVID-19 conditionObjective cognitive functioningMeasures of cognitionTMT-A scoresPlacebo-controlled clinical trialMethodsThis post hoc analysisSubstitution TestTMT-BTMT-APost hoc analysisRandomized controlled trialsDouble-blindClinical implicationsStatistically significant correlationCharacterized cohortClinical trialsCognitionPatient-reported measuresControlled trialsFunctional complaintsAssociation between cognitive functioning, suicidal ideation and suicide attempts in major depressive disorder, bipolar disorder, schizophrenia and related disorders: A systematic review and meta-analysis
Le G, Wong S, Haikazian S, Johnson D, Badulescu S, Kwan A, Gill H, Di Vincenzo J, Rosenblat J, Mansur R, Teopiz K, Rhee T, Ho R, Liao S, Cao B, Schweinfurth-Keck N, Vinberg M, Grande I, Phan L, d'Andrea G, McIntyre R. Association between cognitive functioning, suicidal ideation and suicide attempts in major depressive disorder, bipolar disorder, schizophrenia and related disorders: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 365: 381-399. PMID: 39168166, DOI: 10.1016/j.jad.2024.08.057.Peer-Reviewed Original ResearchBipolar disorderCognitive functionSchizoaffective disorderDepressive disorderExecutive functionMental disordersMeasures of cognitive functionSelf-injurious behaviorTreatable mental disorderGlobal executive functioningEffect size of associationSuicidal ideation/suicide attemptTransdiagnostic associationsSize of associationEmotional inhibitionWorking memoryNegative associationCognitive measuresNeurocognitive deficitsSuicidal ideationSuicide riskCognitive disturbancesImpulse controlProcessing speedMDD